Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 171

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

NOMOGRAMS INCLUDING NUCLEAR MATRIX PROTEIN 22 FOR PREDICTION OF DISEASE RECURRENCE AND PROGRESSION IN PATIENTS WITH Ta, T1 OR CIS TRANSITIONAL CELL CARCINOMA OF THE BLADDER

SHARIAT, SHAHROKH F., ZIPPE, CRAIG, LÜDECKE, GERSON, BOMAN, HANS, SANCHEZ-CARBAYO, MARTA, CASELLA, ROBERTO, MIAN, CHRISTINE, FRIEDRICH, MARTIN G., EISSA, SANAA, AKAZA, HIDEYUKI, SAWCZUK, IHOR, SERRETTA, VINCENZO, HULAND, HARTWIG, HEDELIN, HANS, RUPESH, RAINA, MIYANAGA, NAOTO, SAGALOWSKY, ARTHUR I., WIANS, FRANK, ROEHRBORN, CLAUS G., LOTAN, YAIR, PERROTTE, PAUL, BENAYOUN, SERGE, MARBERGER, MICHAEL J., KARAKIEWICZ, PIERRE I.·2005·Journal of Urology

Abstract

PURPOSE: We developed and validated nomograms that accurately predict disease recurrence and progression in patients with Ta, T1, or CIS transitional cell carcinoma (TCC) of the bladder using a large international cohort. METHODS: Univariate and multivariate logistic regression models targeted histologically confirmed disease recurrence, and focused on 2,542 patients with bladder TCC from 10 participating centers. Variables consisted of pre-cystoscopy voided urine Nuclear Matrix Protein 22 (NMP22) assay, urine cytology, age and gender. Resulting nomograms were internally validated with bootstrapping. Nomogram performance was explored graphically with Loess smoothing plots. RESULTS: Overall 957 patients had recurrent TCC. Tumor grade and stage was available for 898 patients, including 24% grade I, 43% grade II, and 33% grade III; 45% stage Ta, 32% T1 and/or CIS, and 23% T2 or greater. Bootstrap corrected predictive accuracy for any TCC recurrence was 0.842; grade III Ta/T1 or CIS was 0.869; and T2 or higher stage TCC of any grade was 0.858. Virtually perfect performance characteristics were observed for the nomograms predicting any TCC recurrence or grade III Ta/T1 or CIS. The nomogram predicting T2 or higher stage TCC overestimated the observed probability for predicted values greater than 45%. CONCLUSIONS: We developed and internally validated nomograms that incorporate urinary NMP22, cytology, age and gender to predict with high accuracy the probability of disease recurrence and progression in patients with Ta, T1, and/or CIS bladder TCC. These nomograms could provide a means for individualizing followup in patients with Ta, T1, CIS bladder TCC.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/01.ju.0000154696.48217.75

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 1 references

Cited by

See all 171

Metadata

Authors
SHARIAT, S. F., ZIPPE, C., LÜDECKE, G., BOMAN, H., SANCHEZ-CARBAYO, M., CASELLA, R., MIAN, C., FRIEDRICH, M. G., EISSA, S., AKAZA, H., SAWCZUK, I., SERRETTA, V., HULAND, H., HEDELIN, H., RUPESH, R., MIYANAGA, N., SAGALOWSKY, A. I., WIANS, F., ROEHRBORN, C. G., LOTAN, Y., PERROTTE, P., BENAYOUN, S., MARBERGER, M. J., & KARAKIEWICZ, P. I.
Venue
Journal of Urology
Published
2005-05
Volume
173
Issue
5
Pages
1518-1525
ISSN
  • 0022-5347 (ISSN-L)
  • 1527-3792
OpenAlex
W2051955127
Cited by
171
References
1
FWCI
11.47
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: NOMOGRAMS INCLUDING NUCLEAR MATRIX PROTEIN 22 FOR PREDICTION OF DISEASE RECURRENCE AND PROGRESSION IN PATIENTS WITH Ta, T1 OR CIS TRANSITIONAL CELL CARCINOMA OF THE BLADDER. https://app.cochat.ai/papers/10.1097/01.ju.0000154696.48217.75
The paper
SHARIAT, S. F., ZIPPE, C., LÜDECKE, G., BOMAN, H., SANCHEZ-CARBAYO, M., CASELLA, R., MIAN, C., FRIEDRICH, M. G., EISSA, S., AKAZA, H., SAWCZUK, I., SERRETTA, V., HULAND, H., HEDELIN, H., RUPESH, R., MIYANAGA, N., SAGALOWSKY, A. I., WIANS, F., ROEHRBORN, C. G., . . . KARAKIEWICZ, P. I. (2005). NOMOGRAMS INCLUDING NUCLEAR MATRIX PROTEIN 22 FOR PREDICTION OF DISEASE RECURRENCE AND PROGRESSION IN PATIENTS WITH Ta, T1 OR CIS TRANSITIONAL CELL CARCINOMA OF THE BLADDER. Journal of Urology. https://doi.org/10.1097/01.ju.0000154696.48217.75

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.